Lupin Ltd receives 7 observations from USFDA for Goa manufacturing facility

The U.S. FDA has conducted an inspection at Lupin Ltd's manufacturing facility located at Goa, India. The Inspection was conducted from November 10 to November 21, 2025 and closed with the issuance of a Form-483 with seven observations.

We will address the observations and respond to the U.S. FDA within the stipulated timeframe. We are committed to be compliant with CGMP standards across all our facilities.

Shares of Lupin Limited was last trading in BSE at Rs. 2028.70 as compared to the previous close of Rs. 2030.75. The total number of shares traded during the day was 5976 in over 778 trades.

The stock hit an intraday high of Rs. 2037.15 and intraday low of 2022.85. The net turnover during the day was Rs. 12128879.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA Inspection Goa ManufacturingFacility Form483 7Observations